• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

心血管代谢护理中GLP-1受体激动剂和SGLT2抑制剂的多学科应用：糖尿病和心脏病患者的新时代。

The Multidisciplinary Approach to GLP-1 RA and SGLT2 Inhibitors in Cardiometabolic Care: A New Era for Patients with Diabetes and Heart Disease.

作者信息

Lucà Fabiana, Abrignani Maurizio Giuseppe

机构信息

Department of Cardiology, Grande Ospedale Metropolitano (GOM) of Reggio Calabria, Bianchi Melacrino Morelli Hospital, 89129 Reggio Calabria, Italy.

Department of Cardiology, Paolo Borsellino Hospital, 91025 Marsala, Italy.

出版信息

J Clin Med. 2025 Jul 8;14(14):4834. doi: 10.3390/jcm14144834.

DOI:10.3390/jcm14144834
PMID:40725524
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12295575/
Abstract

Editorial [...].

摘要

社论[……]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0db/12295575/19f1935cc6b4/jcm-14-04834-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0db/12295575/e27f8c537310/jcm-14-04834-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0db/12295575/19f1935cc6b4/jcm-14-04834-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0db/12295575/e27f8c537310/jcm-14-04834-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0db/12295575/19f1935cc6b4/jcm-14-04834-g002.jpg

相似文献

1
The Multidisciplinary Approach to GLP-1 RA and SGLT2 Inhibitors in Cardiometabolic Care: A New Era for Patients with Diabetes and Heart Disease.心血管代谢护理中GLP-1受体激动剂和SGLT2抑制剂的多学科应用：糖尿病和心脏病患者的新时代。
J Clin Med. 2025 Jul 8;14(14):4834. doi: 10.3390/jcm14144834.
2
Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes.在全国2型糖尿病患者群体中，GLP-1受体激动剂和SGLT2抑制剂使用者的治疗中断情况。
Diabetologia. 2025 May 2. doi: 10.1007/s00125-025-06439-x.
3
Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.评估三种作用机制（钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽-1受体激动剂和磺脲类药物）在治疗2型糖尿病合并心力衰竭中的效果：一项随机对照试验的系统评价和网状Meta分析
Front Endocrinol (Lausanne). 2025 Jun 10;16:1562815. doi: 10.3389/fendo.2025.1562815. eCollection 2025.
4
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.用于治疗糖尿病和慢性肾脏病患者的胰岛素及降糖药物。
Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2.
5
Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.GLP-1 激动剂和 SGLT2 抑制剂在妊娠和哺乳期对后代结局的影响：证据的系统评价。
Front Endocrinol (Lausanne). 2023 Oct 10;14:1215356. doi: 10.3389/fendo.2023.1215356. eCollection 2023.
6
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.胰高血糖素样肽-1受体激动剂与钠/葡萄糖协同转运蛋白2抑制剂在预防2型糖尿病合并慢性肾脏病患者慢性肾衰竭及死亡方面的比较疗效
Am J Kidney Dis. 2025 Apr 29. doi: 10.1053/j.ajkd.2025.03.016.
7
Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.使用胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白-2抑制剂的医疗保险优势受益人的医疗保健资源利用情况和成本
J Manag Care Spec Pharm. 2025 Jul;31(7):627-640. doi: 10.18553/jmcp.2025.31.7.627.
8
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和醛固酮拮抗剂联合肾素-血管紧张素系统拮抗剂对 2 型糖尿病合并慢性肾脏病患者主要肾脏不良结局的影响：系统评价和网络荟萃分析。
Diabetes Obes Metab. 2022 Nov;24(11):2159-2168. doi: 10.1111/dom.14801. Epub 2022 Jul 15.
9
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.新型降糖药物治疗糖尿病肾病患者心血管和肾脏结局的疗效比较：系统评价和网络荟萃分析。
Diabetes Obes Metab. 2022 Aug;24(8):1448-1457. doi: 10.1111/dom.14702. Epub 2022 Jun 6.
10
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.

本文引用的文献

1
Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation.癌症和心血管疾病的风险因素及预防：先有鸡还是先有蛋的问题。
J Clin Med. 2025 Apr 29;14(9):3083. doi: 10.3390/jcm14093083.
2
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.口服司美格鲁肽与高危2型糖尿病患者的心血管结局
N Engl J Med. 2025 May 29;392(20):2001-2012. doi: 10.1056/NEJMoa2501006. Epub 2025 Mar 29.
3
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
根据SGLT2i使用情况，口服司美格鲁肽与2型糖尿病患者心血管结局：SOUL随机试验的预设分析
Circulation. 2025 Jun 10;151(23):1639-1650. doi: 10.1161/CIRCULATIONAHA.125.074545. Epub 2025 Mar 29.
4
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.司美格鲁肽对比安慰剂在射血分数轻度降低或保留的心衰患者中的疗效：SELECT、FLOW、STEP-HFpEF 和 STEP-HFpEF DM 随机试验的汇总分析。
Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30.
5
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors.在接受 SGLT2 抑制剂治疗的超重或肥胖、糖尿病和 HFpEF 患者中，GLP-1 受体激动剂。
JACC Heart Fail. 2024 Nov;12(11):1814-1826. doi: 10.1016/j.jchf.2024.07.006. Epub 2024 Aug 28.
6
From ECG to Imaging: Challenges in the Diagnosis of Adult Congenital Heart Diseases.从心电图到影像学：成人先天性心脏病诊断中的挑战
J Clin Med. 2024 Aug 18;13(16):4865. doi: 10.3390/jcm13164865.
7
Multidisciplinary Approach in Atrial Fibrillation: As Good as Gold.心房颤动的多学科治疗方法：堪比黄金。
J Clin Med. 2024 Aug 7;13(16):4621. doi: 10.3390/jcm13164621.
8
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.SGLT2 抑制剂与 GLP-1 受体激动剂在 2 型糖尿病中的肾脏和心血管有效性。
J Am Coll Cardiol. 2024 Aug 20;84(8):696-708. doi: 10.1016/j.jacc.2024.06.016.
9
A Look at Primary and Secondary Prevention in the Elderly: The Two Sides of the Same Coin.老年人的一级预防与二级预防：同一枚硬币的两面
J Clin Med. 2024 Jul 25;13(15):4350. doi: 10.3390/jcm13154350.
10
The Multidisciplinary Heart Team in Cardiovascular Medicine: Current Role and Future Challenges.心血管医学中的多学科心脏团队：当前作用与未来挑战
JACC Adv. 2023 Jan 11;2(1):100160. doi: 10.1016/j.jacadv.2022.100160. eCollection 2023 Jan.